Cipher Pharmaceuticals Inc (TO:CPH) — Market Cap & Net Worth
Market Cap & Net Worth: Cipher Pharmaceuticals Inc (CPH)
Cipher Pharmaceuticals Inc (TO:CPH) has a market capitalization of $297.56 Million (CA$411.34 Million) as of June 16, 2026. Listed on the TO stock exchange, this Canada-based company holds position #15014 globally and #448 in its home market, demonstrating a -3.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cipher Pharmaceuticals Inc's stock price CA$16.20 by its total outstanding shares 25391322 (25.39 Million). Review Cipher Pharmaceuticals Inc debt and liabilities to assess the company's total debt and financial obligations.
Cipher Pharmaceuticals Inc Market Cap History: 2015 to 2026
Cipher Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $119.21 Million to $297.56 Million (11.23% CAGR).
Cipher Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cipher Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.39x
Cipher Pharmaceuticals Inc's market cap is 5.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.95x
Cipher Pharmaceuticals Inc's market cap is 9.95 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $90.00 Million | $40.74 Million | -$39.15 Million | 2.21x | N/A |
| 2017 | $90.00 Million | $40.32 Million | $4.40 Million | 2.23x | 20.44x |
| 2018 | $31.41 Million | $22.75 Million | $543.00K | 1.38x | 57.84x |
| 2019 | $27.55 Million | $22.45 Million | $3.24 Million | 1.23x | 8.50x |
| 2020 | $17.08 Million | $21.61 Million | $4.55 Million | 0.79x | 3.76x |
| 2021 | $32.51 Million | $21.94 Million | $7.76 Million | 1.48x | 4.19x |
| 2022 | $70.53 Million | $20.68 Million | $26.64 Million | 3.41x | 2.65x |
| 2023 | $101.76 Million | $21.16 Million | $20.38 Million | 4.81x | 4.99x |
| 2024 | $263.03 Million | $33.36 Million | $11.54 Million | 7.88x | 22.78x |
| 2025 | $276.62 Million | $51.33 Million | $27.81 Million | 5.39x | 9.95x |
Competitor Companies of CPH by Market Capitalization
Companies near Cipher Pharmaceuticals Inc in the global market cap rankings as of June 16, 2026.
Key companies related to Cipher Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Cipher Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Cipher Pharmaceuticals Inc's market cap moved from $119.21 Million to $ 297.56 Million, with a yearly change of 11.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$297.56 Million | +7.57% |
| 2025 | CA$276.62 Million | +5.17% |
| 2024 | CA$263.03 Million | +158.48% |
| 2023 | CA$101.76 Million | +44.27% |
| 2022 | CA$70.53 Million | +116.95% |
| 2021 | CA$32.51 Million | +90.32% |
| 2020 | CA$17.08 Million | -38.00% |
| 2019 | CA$27.55 Million | -12.28% |
| 2018 | CA$31.41 Million | -65.10% |
| 2017 | CA$90.00 Million | 0.00% |
| 2016 | CA$90.00 Million | -24.50% |
| 2015 | CA$119.21 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Cipher Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $297.56 Million USD |
| MoneyControl | $297.56 Million USD |
| MarketWatch | $297.56 Million USD |
| marketcap.company | $297.56 Million USD |
| Reuters | $297.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more